Stocktoria
Jade Biosciences, Inc. JBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-30
Jade Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $93.1M | $53.2M | $64.2M | $38.6M | $15.0M |
| Operating income | -$113.5M | -$74.6M | -$81.4M | -$53.2M | -$23.0M |
| Income tax | $58,000 | $55,000 | $56,000 | $25,000 | $3,000 |
| Net income | -$127.4M | -$69.6M | -$75.5M | -$51.5M | -$23.0M |
| EPS (diluted) | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 |
| Operating cash flow | -$94.7M | -$71.2M | -$56.8M | -$39.1M | -$27.4M |
| Free cash flow | -$94.9M | — | -$56.9M | -$39.3M | -$27.6M |
| Cash & equivalents | $88.4M | $69.4M | $23.5M | $22.4M | $54.2M |
| Total assets | $349.8M | $72.8M | $127.4M | $135.3M | $175.4M |
| Total liabilities | $17.3M | $119.6M | $18.0M | $8.6M | $2.9M |
| Shareholders' equity | $332.5M | -$46.8M | $109.5M | $126.7M | $172.4M |
Source: SEC EDGAR filings · CIK 0001798749 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.